Product pipeline

Our medicines and vaccines in development are classified into three stages: phase I, phase II and phase III. These studies into the safety and efficacy of investigational products provide data to support applications to regulators for approval.

This page provides an outline of the medicines and vaccines in development.

Owing to the nature of drug development, many compounds - especially those in early stages of investigation - may be terminated through the development process. For competitive reasons, new projects in pre-clinical development are not disclosed and some project types may not be identified.

Brand names are trademarks either owned by and/or licensed to GSK or associated companies.

The content of our development pipeline will change over time as new compounds progress from discovery to development and from development to the market.

This annual pipeline information was updated in March 2016.

Key

Key

In-licence or other alliance relationship with third party
^
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
*
Also being developed for indications in another therapeutic area
1
Option-based alliance with Ionis Pharmaceuticals
2
Option-based alliance with Adaptimmune Ltd.
3
Option-based alliance with OncoMed Pharmaceuticals
4
Option-based alliance with Telethon and Ospedale San Raffaele
5
Option-based alliance with Valneva
S
Month of first submission
BLA
Biological Licence Application
MAA
Marketing Authorisation Application (Europe)
NDA
New Drug Application (US)
Phase I
Evaluation of clinical pharmacology, usually conducted in volunteers
Phase II
Determination of dose and initial evaluation of efficacy, conducted in a small number of patients
Phase III
Large comparative study (compound versus placebo and/or established treatment) in patients to establish clinical benefit and safety

MAA and NDA/BLA regulatory review milestones shown in the table below are those that have been achieved. Future filing dates are not included in this list.

Compound Type Indication Phase MAA NDA/BLA
HIV^ and Infectious Diseases scroll or swipe to view full table

dolutegravir + rilpivirine+

HIV integrase inhibitor + non-nucleoside reverse transcriptase inhibitor (NNRTI) HIV infections – two drug maintenance regimen III

3684934

HIV attachment inhibitor HIV infections III

Relenza i.v.+

neuraminidase inhibitor (i.v.) influenza III

cabotegravir + rilpivirine+

HIV integrase inhibitor (long-acting parenteral formulation) HIV pre-exposure prophylaxis II

gepotidacin (2140944)

type 2 topoisomerase inhibitor bacterial infections II

danirixin

chemokine (C-X-C Motif) receptor 2 (CXCR2) antagonist influenza* II

3532795

HIV maturation inhibitor HIV infections II

2838232

HIV maturation inhibitor HIV infections I

32288361

HBV antisense oligonucleotide hepatitis B I

33894041

HBV LICA antisense oligonucleotide hepatitis B I

2878175

nonstructural protein 5B (NS5B) polymerase inhibitor hepatitis C I
Respiratory scroll or swipe to view full table

fluticasone furoate + vilanterol+ + umeclidinium

glucocorticoid agonist + long-acting beta2 agonist + muscarinic acetylcholine antagonist chronic obstructive pulmonary disease (COPD) III

mepolizumab

interleukin 5 (IL5) monoclonal antibody COPD* III

961081+

muscarinic acetylcholine antagonist, beta2 agonist (MABA) COPD II

961081+ fluticasone furoate

muscarinic acetylcholine antagonist, beta2 agonist (MABA) + glucocorticoid agonist COPD II

2245035

toll-like receptor 7 (TLR7) agonist asthma II

2269557

phosphatidylinositol 3-kinase delta (PI3K ) inhibitor asthma and COPD II

2586881+

recombinant human angiotensin converting enzyme 2 (rhACE2) acute lung injury II

2862277

tumour necrosis factor receptor-1 (TNFR1) domain antibody acute lung injury II

danirixin

chemokine (C-X-C Motif) receptor 2 (CXCR2) antagonist COPD* II

fluticasone furoate + vilanterol+ umeclidinium

glucocorticoid agonist + long-acting beta2 agonist + muscarinic acetylcholine antagonist asthma II

losmapimod

p38 kinase inhibitor COPD* II

mepolizumab

interleukin 5 (IL5) monoclonal antibody nasal polyposis* II

mepolizumab 2

interleukin 5 (IL5) monoclonal antibody hypereosinophilic syndrome* II

sirukumab+

interleukin 6 (IL6) human monoclonal antibody severe asthma* II

3008348

alpha V beta 6 integrin antagonist idiopathic pulmonary fibrosis I
Oncology scroll or swipe to view full table

33777942

NY-ESO-1 autologous engineered TCR-T cells (engineered TCR) sarcoma, multiple myeloma, non-small cell lung cancer, melanoma and ovarian cancer II

tarextumab3

notch 2/3 monoclonal antibody small cell lung cancer I

brontictuzumab3

notch 1 monoclonal antibody solid tumours and haematological malignancies I

3174998+

OX40 agonist monoclonal antibody solid tumours and haematological malignancies I

2879552

lysine-specific demethylase 1 (LSD1) inhibitor acute myeloid leukemia and small cell lung cancer I

2857916+

beta cell maturation antigen antibody drug conjugate multiple myeloma I

2849330

erb-b2 receptor tyrosine kinase 3 (ErbB3) monoclonal antibody solid tumours I

2816126

enhancer of zeste homologue2 (EZH2) inhibitor solid tumours and haematological malignancies I

2636771

phosphatidylinositol 3-kinase (PI3K) beta inhibitor castration resistant prostate cancer I

2256098

focal adhesion kinase inhibitor mesothelioma I

525762

BET family bromodomain inhibitor solid tumours and haematological malignancies I
Immuno-inflammation scroll or swipe to view full table

sirukumab+

interleukin 6 (IL6) human monoclonal antibody rheumatoid arthritis* III

sirukumab+

interleukin 6 (IL6) human monoclonal antibody giant cell arteritis* III

Benlysta

B lymphocyte stimulator monoclonal antibody (s.c.) systemic lupus erythematosus* III

Benlysta

B lymphocyte stimulator monoclonal antibody (i.v.) vasculitis* III

Benlysta

B lymphocyte stimulator monoclonal antibody (i.v.) transplant rejection* II

Benlysta + Rituxan+

B lymphocyte stimulator monoclonal antibody (s.c.) + cluster of differentiation 20 (CD20) monoclonal antibody (i.v.) Sjogren's syndrome II

3196165+

granulocyte macrophage colony-stimulating factor monoclonal antibody rheumatoid arthritis II

2330811

oncostatin M (OSM) monoclonal antibody systemic sclerosis I

2618960

interleukin 7 (IL7) receptor monoclonal antibody Sjogren's syndrome I

2646264

spleen tyrosine kinase (Syk) inhibitor (topical) chronic urticaria I

2831781+

lymphocyte activation gene 3 (LAG3) protein monoclonal antibody autoimmune disease I

2982772

receptor-interacting protein 1 (RIP1) kinase inhibitor psoriasis, rheumatoid arthritis and ulcerative colitis I

3050002+

chemokine (C-C motif) ligand 20 chemokine (C-C motif) ligand 20 psoriatic arthritis I

3117391+

macrophage targeted histone deacetylase inhibitor rheumatoid arthritis I

3179106

rearranged during transfection (RET) kinase inhibitor inflammatory disorders of the bowel I
Rare diseases scroll or swipe to view full table

2696273+

ex-vivo stem cell gene therapy adenosine deaminase severe combined immune deficiency (ADA-SCID) Submitted S: May15

2998728+

transthyretin (TTR) production inhibitor transthyretin-mediated amyloidosis III

mepolizumab

interleukin 5 (IL5) monoclonal antibody eosinophilic granulomatosis with polyangiitis* III

2398852+ + 2315698+

serum amyloid P component (SAP) monoclonal antibody + SAP depleter (CPHPC) amyloidosis II

2696274+

ex-vivo stem cell gene therapy metachromatic leukodystrophy II

2696275+

ex-vivo stem cell gene therapy Wiscott-Aldrich syndrome II

26962774

ex-vivo stem cell gene therapy beta-thalassemia I
Vaccines scroll or swipe to view full table

Shingrix(Zoster Vaccine)

recombinant Herpes Zoster prophylaxis III

MMR

live attenuated measles, mumps, rubella prophylaxis III (US) N/A

Ebola+

recombinant viral vector Ebola haemorrhagic fever prophylaxis II

Group B Streptococcus

conjugated Group B streptococcus prophylaxis (maternal immunisation) II

S. pneumoniae next generation+

recombinant – conjugated Streptococcus pneumoniae disease prophylaxis II

COPD+

recombinant reduction of the frequency of COPD exacerbations associated with non-typeable Haemophilus influenzae and Moraxella catarrhalis II

Hepatitis C+

recombinant viral vector hepatitis C virus prophylaxis II

Malaria next generation+

recombinant malaria prophylaxis (Plasmodium falciparum) II

Men ABCWY

recombinant – conjugated meningococcal A,B,C,W and Y disease prophylaxis in adolescents II

Pseudomonasℑ

recombinant pseudomonas infection prophylaxis II

Shigella+

conjugated and outer membrane Shigella diarrhea prophylaxis II

TuberculosisTuberculosis+

recombinant tuberculosis prophylaxis II

RSV

recombinant respiratory syncytial virus prophylaxis (maternal immunisation) II

RSV

replication-defective recombinant viral vector respiratory syncytial virus prophylaxis I

HIV+

recombinant proteins HIV infection prophylaxis I
Other pharmaceuticals: Metabolic scroll or swipe to view full table

retosiban

oxytocin antagonist spontaneous pre-term labour III

daprodustat (1278863)

prolyl hydroxylase inhibitor anaemia associated with chronic renal disease II

2330672

ileal bile acid transport (IBAT) inhibitor cholestatic pruritus II

camicinal

motilin receptor agonist delayed gastric emptying II

Eperzan/Tanzeum (albiglutide)

glucagon-like peptide 1 (GLP1) receptor agonist type 1 diabetes II

losmapimod

p38 kinase inhibitor focal segmental glomerular sclerosis* II

otelixizumab

cluster of differentiation 3 (CD3) new onset type 1 diabetes II

daprodustat (1278863)

prolyl hydroxylase inhibitor (topical) monoclonal antibody wound healing I

2798745

transient receptor potential cation channel V4 (TRPV4) antagonist heart failure I

2881078

selective androgen receptor modulator muscle wasting I

oxytocin (inhaled)+

oxytocin postpartum hemorrhage I
Other pharmaceuticals: Dermatology scroll or swipe to view full table

chlorhexidine

cationic polybiguanide (topical) prevention of omphalitis Submitted S: Oct15

2894512+

non-steroidal anti-inflammatory (topical) atopic dermatitis II

2894512+

non-steroidal anti-inflammatory (topical) psoriasis II

2981278

ROR gamma inverse agonist (topical) psoriasis II

umeclidinium

muscarinic acetylcholine antagonist (topical) hyperhidrosis* II

mepolizumab

interleukin 5 (IL5) monoclonal antibody severe atopic dermatitis* I
Other pharmaceuticals: Neurosciences scroll or swipe to view full table

933776

beta amyloid monoclonal antibody geographic retinal atrophy II

Benlysta

B lymphocyte stimulator monoclonal antibody (i.v.) myasthenia gravis* II

rilapladib

lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor Alzheimer's disease II

n/a

ocular target LICA antisense oligonucleotide1 geographic atrophy age-related macular disease I

There are no results for your selection.

Back to top